Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma
IntroductionCombination immunotherapy with ipilimumab and nivolumab has improved long-term progression-free and overall survival in patients with metastatic melanoma. Unfortunately, a high percentage of patients develop immune-related side effects, including endocrinopathy. The incidence and timing...
Sábháilte in:
| Príomhchruthaitheoirí: | , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
Frontiers Media S.A.
2026-05-01
|
| Sraith: | Frontiers in Endocrinology |
| Ábhair: | |
| Rochtain ar líne: | https://www.frontiersin.org/articles/10.3389/fendo.2026.1827644/full |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|